MOTIF BIO ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR ICLAPRIM FOR TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

PDUFA action date set for February 13, 2019 NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: $MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S. … Continue reading MOTIF BIO ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR ICLAPRIM FOR TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS